Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
21
OM Quote, Financials, Valuation and Earnings
Last price:
$17.54
Seasonality move
:
-30.5%
Day range:
$17.53 - $18.57
52-week range:
$5.85 - $68.17
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.66x
P/B ratio:
1.88x
Volume:
294.9K
Avg. volume:
448.7K
1-year change:
-73.51%
Market cap:
$311.9M
Revenue:
$113.7M
EPS (TTM):
-$29.16
Analysts' Opinion
-
Consensus RatingOutset Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.50, Outset Medical has an estimated upside of 39.21% from its current price of $17.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 14.77% downside risk from its current price of $17.60.
Fair Value
-
According to the consensus of 5 analysts, Outset Medical has 39.21% upside to fair value with a price target of $24.50 per share.
OM vs. S&P 500
-
Over the past 5 trading days, Outset Medical has underperformed the S&P 500 by -15.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Outset Medical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Outset Medical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Outset Medical reported revenues of $29.8M.
Earnings Growth
-
Outset Medical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Outset Medical reported earnings per share of -$3.66.
Enterprise value:
220.9M
EV / Invested capital:
--
Price / LTM sales:
0.66x
EV / EBIT:
--
EV / Revenue:
1.92x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$41.4M
Return On Assets:
-37.18%
Net Income Margin (TTM):
-98.74%
Return On Equity:
-140.06%
Return On Invested Capital:
-44.16%
Operating Margin:
-55.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $118.3M | $125.1M | $115.3M | $28.2M | $29.8M | |
| Gross Profit | $19.8M | $30.8M | $41.4M | $8.2M | $11.1M | |
| Operating Income | -$168M | -$163.2M | -$92.9M | -$36.9M | -$16.4M | |
| EBITDA | -$158.3M | -$146.7M | -$86.3M | -$32.4M | -$20.8M | |
| Diluted EPS | -$52.95 | -$50.77 | -$29.16 | -$11.77 | -$3.66 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $321.7M | $377.4M | $337.3M | $325.4M | $286.6M | |
| Total Assets | $379.8M | $431.7M | $362.7M | $346.2M | $301.2M | |
| Current Liabilities | $34.8M | $48.9M | $44.3M | $50.7M | $34.2M | |
| Total Liabilities | $73.2M | $86.3M | $146.4M | $253M | $131.3M | |
| Total Equity | $306.6M | $345.5M | $216.3M | $93.2M | $169.9M | |
| Total Debt | $29.7M | $29.8M | $96.5M | $196.8M | $94.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$152.2M | -$132.5M | -$96.1M | -$45.9M | -$25.7M | |
| Cash From Investing | -$30.3M | $21.4M | $84.9M | -$59M | -$78.1M | |
| Cash From Financing | $74.5M | $107M | $54.9M | $68.6M | $55.7M | |
| Free Cash Flow | -$159.8M | -$135.5M | -$96.7M | -$46.3M | -$25.8M | |
OM
Sector
Market Cap
$311.9M
$34.4M
Price % of 52-Week High
25.82%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-73.51%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$19.25
200-day SMA
Buy
Level
$13.69
Bollinger Bands (100)
Buy
Level
10.21 - 19.17
Chaikin Money Flow
Sell
Level
-912.9K
20-day SMA
Sell
Level
$19.53
Relative Strength Index (RSI14)
Sell
Level
40.27
ADX Line
Sell
Level
31.69
Williams %R
Buy
Level
-86.2682
50-day SMA
Sell
Level
$18.86
MACD (12, 26)
Buy
Level
5.11
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Sell
Level
-368.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.2915)
Sell
CA Score
(Annual)
Level (-3.0285)
Buy
Beneish M-Score
(Annual)
Level (-2.6922)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.6321)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Stock Forecast FAQ
In the current month, OM has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The OM average analyst price target in the past 3 months is $24.50.
-
Where Will Outset Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Outset Medical share price will rise to $24.50 per share over the next 12 months.
-
What Do Analysts Say About Outset Medical?
Analysts are divided on their view about Outset Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Outset Medical is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Outset Medical's Price Target?
The price target for Outset Medical over the next 1-year time period is forecast to be $24.50 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is OM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Outset Medical is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OM?
You can purchase shares of Outset Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Outset Medical shares.
-
What Is The Outset Medical Share Price Today?
Outset Medical was last trading at $17.54 per share. This represents the most recent stock quote for Outset Medical. Yesterday, Outset Medical closed at $17.60 per share.
-
How To Buy Outset Medical Stock Online?
In order to purchase Outset Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
72
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
